Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies

30 Oct 2021

Abstract excerpt

BCL-2 overexpression has been associated with resistance to chemotherapy and reduced survival in acute myeloid leukemia (AML), but few data are available in elderly patients, a subset accounting for majority of AML cases and with dismal prognosis. We retrospectively analyzed 113 AML patients aged ≥65 years treated with 3 + 7 chemotherapy (n = 51) or hypomethylating agents (HMAs) (n = 62), evaluating the role of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34768616
DOI: 10.3390/jcm10215096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic StrategiesPMID 34768616Read ↗

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignanciesSemantic proximity Read ↗

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.Semantic proximity Read ↗

New Treatment Options for Older Patients with Acute Myeloid Leukemia.Semantic proximity Read ↗

Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.Semantic proximity Read ↗

Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcomeSemantic proximity Read ↗

BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients.Semantic proximity Read ↗

Development of a clinical prediction model for sensitivity to combination therapy of Bcl-2 inhibitors and hypomethylating agents in elderly/unfit patients with acute myeloid leukemiaSemantic proximity Read ↗

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AMLSemantic proximity Read ↗

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agentsSemantic proximity Read ↗

The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patientsSemantic proximity Read ↗

Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)Semantic proximity Read ↗

A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.